After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
XFOR belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of X4 Pharmaceuticals Inc is $166.55M. A total of 2.31 million shares were traded on the day, compared to an average of 2.02M shares.
In the most recent transaction, Mostafa Adam S. sold 27,721 shares of XFOR for 1.01 per share on Feb 12. After the transaction, the Chief Financial Officer now owns 52,500 company shares. In a previous transaction on Feb 12, Ragan Paula sold 21,695 shares at 1.01 per share. XFOR shares that President and CEO owns now total 814,746.
Among the insiders who sold shares, DiBiase Mary disposed of 3,683 shares on Feb 12 at a per-share price of $1.01. This resulted in the Chief Operating Officer holding 307,161 shares of XFOR after the transaction. In another insider transaction, Taveras Arthur sold 787 shares at $1.01 per share on Feb 12. Company shares held by the Chief Scientific Officer now total 248,536.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for XFOR in the last 3 months, the mean price target is $3.26 with high estimates of $5.00 and low estimates of $1.00. In terms of 52-week highs and lows, XFOR has a high of $2.58 and a low of $0.57.
As of this writing, XFOR has an earnings estimate of -$0.15 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.33 in the last quarter, which was -106.20% lower than expectations of -$0.16.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. XFOR’s latest balance sheet shows that the firm has $81.79M in Cash & Short Term Investments as of fiscal 2021. There were $39.78M in debt and $14.02M in liabilities at the time. Its Book Value Per Share was $0.41, while its Total Shareholder’s Equity was $64.41M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XFOR is Buy with a score of 4.67.
